Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYNP 101

Next Previous
Drug Profile

SYNP 101

Alternative Names: SYNP-101; Synthetic psilocybin - Ceruvia Lifesciences

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ceruvia Lifesciences
  • Developer Ceruvia Lifesciences; Yale University School of Medicine
  • Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
  • Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholism; Obsessive-compulsive disorders
  • No development reported Cluster headache; Migraine

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Cluster-headache in USA (PO)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Migraine in USA (PO)
  • 31 Oct 2024 B.More announces intention to submit NDA to US FDA for Opioid related disorders

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top